共 50 条
p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis
被引:270
作者:
Wang, Xuyi
[1
,2
,3
]
Simpson, Evan R.
[1
,2
,4
]
Brown, Kristy A.
[1
,2
,3
]
机构:
[1] Hudson Inst Med Res, Metab & Canc Lab, Ctr Canc Res, Clayton, Vic 3168, Australia
[2] Hudson Inst Med Res, Metab & Canc Lab, Ctr Endocrinol & Metab, Clayton, Vic 3168, Australia
[3] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia
[4] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia
基金:
澳大利亚国家健康与医学研究理事会;
关键词:
ELEVATED AROMATASE EXPRESSION;
POSITIVE BREAST-CANCER;
LI FRAUMENI SYNDROME;
SUPPRESSOR P53;
ESTROGEN;
OBESITY;
PROTEIN;
POSTMENOPAUSAL;
INHIBITOR;
TISSUE;
D O I:
10.1158/0008-5472.CAN-15-0563
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The tumor suppressor p53 has established functions in cancer. Specifically, it has been shown to cause cell-cycle arrest and apoptosis in response to DNA damage. It is also one of the most commonly mutated or silenced genes in cancer and for this reason has been extensively studied. Recently, the role of p53 has been shown to go beyond its effects on cell cycle and apoptosis, with effects on metabolism emerging as a key contributor to cancer growth in situations where p53 is lost. Beyond this, the role of p53 in the tumor microenvironment is poorly understood. The publication by Wang and colleagues demonstrates for the first time that p53 is a key negative regulator of aromatase and, hence, estrogen production in the breast tumor microenvironment. It goes further by demonstrating that an important regulator of aromatase, the obesity-associated and tumor-derived factor prostaglandin E-2, inhibits p53 in the breast adipose stroma. This review presents these findings in the context of established and emerging roles of p53 and discusses possible implications for the treatment of breast cancer. (C) 2015 AACR.
引用
收藏
页码:5001 / 5007
页数:7
相关论文
共 50 条